Trial Profile
A Non-interventional Study to Assess the Safety and Efficacy of First Line Therapy With Vectibix® in Combination With FOLFIRI and to Validate a Prognostic Score in Adult Patients With RAS Wild-type Metastatic Colorectal Cancer in a Real World Setting (VALIDATE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VALIDATE
- Sponsors iOMEDICO AG
- 24 Oct 2023 Updated second interim analysis Results presented at the 48th European Society for Medical Oncology Congress
- 16 Oct 2023 According to an Amgen media release, updated interim results from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.
- 01 Jul 2021 Status changed from recruiting to active, no longer recruiting.